UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Thrombosis in immune thrombocytopenia — current status and future perspectives

British journal of haematology, 2021-09, Vol.194 (5), p.822-834

2021

Volltextzugriff (PDF)

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety

Cancers, 2023-03, Vol.15 (6), p.1819

2023

Volltextzugriff (PDF)

How to undertake procedures while on antiplatelet agents: a hematologist's view

Research and practice in thrombosis and haemostasis, 2024-08, Vol.8 (6), p.102539, Article 102539

2024

Volltextzugriff (PDF)

Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)

Haematologica (Roma), 2020-03, Vol.105 (3), p.e141-e143

2020

Volltextzugriff (PDF)

Non‐factor therapies for bleeding disorders: A primer for the general haematologist

EJHaem, 2022-08, Vol.3 (3), p.584-595

2022

Volltextzugriff (PDF)

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

HemaSphere, 2020-04, Vol.4 (2), p.e350-n/a

2020

Volltextzugriff (PDF)

Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity

Cancers, 2023-04, Vol.15 (7), p.2154

2023

Volltextzugriff (PDF)

Management of haemostatic complications of chimaeric antigen receptor T‐cell therapy

British journal of haematology, 2022-05, Vol.197 (3), p.250-259

2022

Volltextzugriff (PDF)

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma

Therapeutic Advances in Hematology, 2019, Vol.10, p.2040620719854171-2040620719854171

2019

Volltextzugriff (PDF)

Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis

Oncoimmunology, 2021-01, Vol.10 (1), p.1859263-1859263

2021

Volltextzugriff (PDF)

The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies

British journal of haematology, 2022-02, Vol.196 (3), p.488-506

2022

Volltextzugriff (PDF)

Challenges in managing patients on anticoagulation: Thrombocytopenia, resumption after bleeding and recurrent thrombosis

Journal of the Royal College of Physicians of Edinburgh, 2022-12, Vol.52 (4), p.341-349

2022

Volltextzugriff (PDF)

Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations

British journal of haematology, 2018-11, Vol.183 (4), p.538-556

2018

Volltextzugriff (PDF)

Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-01, Vol.28 (1), p.42-45

2022

Volltextzugriff (PDF)

The prothrombotic tendency of metabolic-associated fatty liver disease

Journal of thrombosis and haemostasis, 2023-11, Vol.21 (11), p.3045-3055

2023

Volltextzugriff (PDF)

Practical management of the haemorrhagic complications of myeloproliferative neoplasms

British journal of haematology, 2022-11, Vol.199 (3), p.313-321

2022

Volltextzugriff (PDF)

Management of venous thromboembolism in athletes

Blood reviews, 2021-05, Vol.47, p.100780-100780, Article 100780

2021

Volltextzugriff (PDF)

Dilemmas in hematology: consults in patients with arterial thrombosis

Journal of thrombosis and haemostasis, 2023-03, Vol.21 (3), p.421-432

2023

Volltextzugriff (PDF)

Heparin – Messias or Verschlimmbesserung?

Journal of thrombosis and haemostasis, 2021-10, Vol.19 (10), p.2373-2382

2021

Volltextzugriff (PDF)

Management of bleeding and procedures in patients on antiplatelet therapy

Blood reviews, 2020-01, Vol.39, p.100619-100619, Article 100619

2020

Volltextzugriff (PDF)

A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place

Journal of neurology, 2021-07, Vol.268 (7), p.2390-2401

2021

Volltextzugriff (PDF)

Anticoagulation in chronic kidney disease: current status and future perspectives

Journal of thrombosis and haemostasis, 2024-02, Vol.22 (2), p.323-336

2024

Volltextzugriff (PDF)

Acute Abdominal and Pelvic Complications in Patients with Non-Promyelocytic Acute Myeloid Leukaemia Undergoing Intensive Induction Chemotherapy Are Associated with Favorable Prognosis

Blood, 2023-11, Vol.142 (Supplement 1), p.5858-5858

2023

Volltextzugriff (PDF)

Thromboprophylaxis in COVID-19 – Rationale and considerations

Advances in biological regulation, 2021-08, Vol.81, p.100819-100819, Article 100819

2021

Volltextzugriff (PDF)

The problem of under-diagnosis and over-diagnosis of pulmonary embolism

Thrombosis research, 2019-05, Vol.177, p.122-129

2019

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(66)

Publikationsform

Sprache

Englisch
(74)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Thrombosis in immune thrombocytopenia — current status and future perspectives

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety

How to undertake procedures while on antiplatelet agents: a hematologist's view

Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)

Non‐factor therapies for bleeding disorders: A primer for the general haematologist

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity

Management of haemostatic complications of chimaeric antigen receptor T‐cell therapy

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma

Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis

The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies

Challenges in managing patients on anticoagulation: Thrombocytopenia, resumption after bleeding and recurrent thrombosis

Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations

Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature

The prothrombotic tendency of metabolic-associated fatty liver disease

Practical management of the haemorrhagic complications of myeloproliferative neoplasms

Management of venous thromboembolism in athletes

Dilemmas in hematology: consults in patients with arterial thrombosis

Heparin – Messias or Verschlimmbesserung?

Management of bleeding and procedures in patients on antiplatelet therapy

A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place

Anticoagulation in chronic kidney disease: current status and future perspectives

Acute Abdominal and Pelvic Complications in Patients with Non-Promyelocytic Acute Myeloid Leukaemia Undergoing Intensive Induction Chemotherapy Are Associated with Favorable Prognosis

Thromboprophylaxis in COVID-19 – Rationale and considerations

The problem of under-diagnosis and over-diagnosis of pulmonary embolism

Suchergebnisse filtern